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Depending on populations studied and applied methods and definitions, the prevalence of treatment-resistant 
hypertension varies from 3% to 30%.1,2 The SYMPLICITY 
studies3–5 demonstrated that in this indication catheter-based 
endovascular sympathetic renal denervation (RDN) by 
means of  low-frequency energy is feasible. It entails a 25- to 
30-mm Hg decrease in office systolic blood pressure, 84% of 
patients achieving a decrease in office systolic blood pres-
sure of ≥10 mm Hg with a rate of procedural adverse events 
<5% assessed 6 months after RDN.4 However, as reviewed 
Abstract—Based on the SYMPLICITY studies and CE (Conformité Européenne) certification, renal denervation is currently 
applied as a novel treatment of resistant hypertension in Europe. However, information on the proportion of patients 
with resistant hypertension qualifying for renal denervation after a thorough work-up and treatment adjustment remains 
scarce. The aim of this study was to investigate the proportion of patients eligible for renal denervation and the reasons for 
noneligibility at 11 expert centers participating in the European Network COordinating Research on renal Denervation in 
 treatment-resistant hypertension (ENCOReD). The analysis included 731 patients. Age averaged 61.6 years, office blood 
pressure at screening was 177/96 mm Hg, and the number of blood pressure–lowering drugs taken was 4.1. Specialists 
referred 75.6% of patients. The proportion of patients eligible for renal denervation according to the SYMPLICITY HTN-
2 criteria and each center’s criteria was 42.5% (95% confidence interval, 38.0%–47.0%) and 39.7% (36.2%–43.2%), 
respectively. The main reasons of noneligibility were normalization of blood pressure after treatment adjustment (46.9%), 
unsuitable renal arterial anatomy (17.0%), and previously undetected secondary causes of hypertension (11.1%). In 
conclusion, after careful screening and treatment adjustment at hypertension expert centers, only ≈40% of patients referred 
for renal denervation, mostly by specialists, were eligible for the procedure. The most frequent cause of ineligibility 
(approximately half of cases) was blood pressure normalization after treatment adjustment by a hypertension specialist. 
Our findings highlight that hypertension centers with a record in clinical experience and research should remain the 
gatekeepers before renal denervation is considered.  (Hypertension. 2014;63:1319-1325.) • Online Data Supplement
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elsewhere,6,7 blood pressure decrease observed after RDN 
is highly variable8 and probably much less than previously 
thought, especially when ambulatory blood pressure monitor-
ing is used.8–10 Furthermore, stenosis11,12 and damage13 of the 
renal arteries can occur after RDN, and the long-term effect 
of RDN on renal function is still unclear.5,14,15 Hence, until 
more and better evidence is available, RDN should remain 
the last resort in patients with truly resistant hypertension.6,7 
Accordingly, several national and international consensus 
papers16,17 have proposed guidelines for evaluation and man-
agement of patients with resistant hypertension before con-
sidering RDN. The proportion of patients with truly resistant 
hypertension eligible for RDN and the reasons of noneligibil-
ity after thorough screening and optimization of drug treatment 
in expert centers remain elusive. In this study, we reviewed 
the reasons for noneligibility at 11 hypertension expert cen-
ters performing RDN for treatment-resistant hypertension and 
collaborating within the European Network COordinating 
research on Renal Denervation (ENCOReD).8
Methods
Patients
We performed systematic reviews of the literature published else-
where6,7 and identified ENCOReD centers engaging in RDN. At the 
fourth ENCOReD network meeting, held in Leuven on April 26, 2013, 
all 12 centers involved in ENCOReD were invited and accepted to 
take part in this study. Eventually, 1 center was removed from the final 
analysis because not all information required for the present analysis 
could be retrieved from the local database. The 11 other contributing 
centers provided information on 731 consecutive patients referred for 
RDN. All patients underwent a center-specific 3- to 6-month diag-
nostic and therapeutic work-up. The eligibility criteria for RDN at 
the participating centers were similar to those of the SYMPLICITY 
studies with the following differences: (1) office systolic blood pres-
sure should be ≥140 mm Hg (3 centers) or ≥160 mm Hg in patients 
without diabetes mellitus or ≥150 mm Hg in patients with diabetes 
mellitus (3 centers), or the 24-hour systolic blood pressure should 
be ≥130 mm Hg, irrespective of the level of office blood pressure (8 
centers); (2) patients with white-coat–resistant hypertension were not 
eligible (8 centers); (3) evaluation of renal artery anatomy by com-
puted tomography or MRI was mandatory (all centers); (4) patients 
with >2 renal arteries were eligible provided that the length and diam-
eter of the arteries fulfilled the SYMPLICITY criteria (all centers); 
(5) the lower limit of the estimated glomerular filtration rate (eGFR) 
using the modification of diet in renal disease formula was 30 mL/
min per 1.73 m2 (5 centers) or 45 mL/min per 1.73 m2 (3 centers); in 
1 center, patients were excluded if serum creatinine was >200 μmol/L 
and 2 centers did not set limits to eGFR; and (6) drug adherence was 
assessed according to electronic compliance monitoring (1 center), 
plasma dosage of drugs and their metabolites (1 center), pharmacy 
refill (1 center), witnessed drug intake (3 centers), or the Morisky 
adherence questionnaire (1 center).
Investigators completed a template data sheet for all these pa-
tients. It collected information on anthropometric characteristics 
of the referred patients, their office and ambulatory blood pressure, 
drug treatment at the first visit, eligibility for RDN according to the 
SYMPLICITY HTN-2 inclusion and exclusion criteria (E1)4 and the 
centers’ own assessment (E2), and reasons of noneligibility. The com-
prehensive list of noneligibility criteria included older age/frailty; 
morbid obesity; altered renal function; previous cholesterol emboli 
or diffuse atherosclerosis; white-coat–resistant hypertension (con-
ventional blood pressure ≥140/90 mm Hg but daytime ambulatory 
blood pressure <135/85 mm Hg); renal artery stenosis; renal artery 
stenting; other anatomic reasons precluding RDN; primary aldoste-
ronism; pheochromocytoma; other causes of secondary hypertension; 
blood pressure controlled or substantially improved after treatment 
adjustment, including or not low-dose (25–50 mg) spironolactone; 
poor drug adherence; and patient or referring physician’s refusal. 
Furthermore, participants had the possibility to add other reasons as 
free text. For each patient considered noneligible by the center (E2), 
>1 reason of noneligibility could be provided.
Statistical Methods
We used SAS software (SAS Institute, Cary, NC), version 9.3, for 
database management and statistical analysis. Continuous data are 
presented as mean±SD and categorical data as frequencies and per-
centages. We compared means and proportions by a large sample z 
test and the χ2 statistic, respectively. We applied a κ statistic to assess 
agreement between diagnostic criteria. We applied stepwise logistic 
regression to search for variables associated with an increased likeli-
hood of being eligible for RDN. P values for independent variables 
to enter and stay the model were set at 0.15. The variables considered 
for entering into the models were sex, age, body mass index, baseline 
systolic blood pressure, eGFR, total number of drugs taken, a history 
of diabetes mellitus, coronary artery disease, stroke, and peripheral 
artery disease. Odds ratios express the independent increase in risks 
associated with a 1-SD increase in continuous covariables or a condi-
tion of interest (eg, sex). Significance was a 2-sided P value of ≤0.05.
Results
Baseline Characteristics
Information was obtained on 731 subjects. Specialists referred 
75.6% of patients (mostly cardiologists and nephrologists), 
and general practitioners referred 24.4% of patients. Baseline 
blood pressure, the frequency of comorbidities, drug treat-
ment score, and drug classes (Table 1) were similar to those 
observed in SYMPLICITY HTN-2.4 Notably, at the first visit 
to the referral center, 14.9% of patients had no drug inhibiting 
the renin–angiotensin system, 27.2% had no calcium antag-
onist, and 18.0% had no diuretic (Table 2; Figure S1 in the 
online-only Data Supplement). Furthermore, 21.5% were pre-
scribed 2 or even 3 drugs inhibiting the renin–angiotensin sys-
tem. The proportion of patients under spironolactone was low 
(26.0%) even in patients with eGFR ≥45 (28.1%) or ≥60 mL/
min per 1.73 m2 (27.0%). The proportion of patients who had 
taken spironolactone in the past was 20.9% (95% confidence 
interval [CI], 17.1%–24.7%), 22.4% (CI, 18.2%–26.6%), and 
22.8% (CI, 18.1%–27.5%) in the whole group and in patients 
with eGFR ≥45 or ≥60 mL/min per 1.73 m2, respectively.
Eligibility Status
Fewer than half of patients were eligible for RDN, both 
according to the SYMPLICITY HTN-2 criteria (E1, 42.5%; 
CI, 38.0%–47.0%) and the centers’ own judgment (E2, 39.7%; 
CI, 36.2%–43.2%), with substantial variability between cen-
ters (Table 3). In patients with apparently resistant hyperten-
sion (office systolic blood pressure ≥140 mm Hg, despite 
prescription of ≥3 antihypertensive drug classes; n=601) and 
in patients with office systolic blood pressure ≥160 mm Hg 
and eGFR ≥45 mL/min per 1.73 m2 (n=433), the propor-
tion of eligible patients was slightly higher (E1, 45.4% and 
E2, 40.1%; and E1, 60.2% and E2, 48.3%, respectively). 
Eligibility status was moderately consistent between E1 and 
E2 (κ coefficient of agreement, 0.49). As may be expected, 
the proportion of eligible patients was higher in the subset 
referred by specialists than in patients referred by general 
practitioners (E1, 47.0% versus 31.6%; P<0.001; and E2, 
43.6% versus 27.5%; P<0.001).
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Determinants of Eligibility
Compared with patients considered ineligible by the centers 
(non-E2), eligible patients (E2) were slightly but significantly 
younger, had a significantly higher office and ambulatory blood 
pressure, were taking more drug classes, and had a higher eGFR 
(Table 1). In a stepwise logistic regression model, age, base-
line blood pressure, number of blood pressure–lowering drugs, 
eGFR, and body mass index were associated with the likelihood 
of eligibility for RDN. Eligibility for RDN was independently 
related with 1-SD increase in office systolic blood pressure 
(odds ratio [OR], 1.87; CI, 1.54–2.25; P<0.001), increase in the 
number of blood pressure–lowering drugs (OR, 1.31; CI, 1.09–
1.57; P=0.004), and increase in eGFR (OR, 1.25; CI, 1.04–1.51; 
P=0.02), lower age (OR, 0.72; CI, 0.59–0.87; P=0.001), and 
lower body mass index (OR, 0.84; CI, 0.70–1.01; P=0.064).
Reasons for noneligibility with a frequency of ≥5% 
(Figures 1 and 2; Table S1) were (1) controlled or substantially 
improved blood pressure after treatment adjustment (46.9%), 
in 49.7% of cases using a regimen including low-dose spi-
ronolactone (25–50 mg/d); (2) anatomic reasons (17.0%, renal 
artery stenosis, history of renal stenting, or other anatomic rea-
sons); (3) secondary hypertension (11.1%, most often primary 
aldosteronism but also including autonomic dysfunction and 
hypercortisolism); (4) decreased renal function (9.1%); (5) 
older age and frailty (7.9%); (6) white-coat–resistant hyperten-
sion (7.7%); and (7) poor drug adherence (7.7%).
A nonexhaustive list of other reasons of noneligibility encom-
passed morbid obesity (n=17); patient (n=10) or referring phy-
sician (n=3) refusing the procedure; diffuse atherosclerosis or 
previous cholesterol emboli (n=2); proteinuria (n=2); clear cell 
carcinoma/renal mass (n=2); subarachnoid hemorrhage (n=1) or 
unstable angina pectoris (n=2) before RDN; nephrotic protein-
uria because of light chain disease (n=1); bilateral fibromuscular 
dysplasia (n=1); hydronephrosis (n=1); primary hyperparathy-
roidism (n=1); chronic autoimmune disease (n=1); psychiatric ill-
ness (n=1); or alcohol abuse (n=1). Of note, in 26.3% of patients 
deemed ineligible, ≥2 reasons of noneligibility were present.
Discussion
In this multicenter cohort, only ≈40% of patients referred for 
RDN, mostly by specialists, were eligible for the procedure, 
according to the SYMPLICITY HTN-2 criteria, as well as 
according to the centers’ own judgment. These data confirm at 
the European level the results obtained by Verloop et al18 in a 
Dutch single-center cohort, also included in ENCOReD. The 
proportion of less complex, standard patients with resistant 
hypertension in whom RDN seems both feasible and justi-
fied is probably still an order of magnitude lower (7.5% in 
patients with resistant hypertension hospitalized for hyper-
tension in a French third referral center; 2.6% according to 
a recent US chart review)2,19 and might further decrease if all 
patients would be assessed for drug adherence20 or would have 
received maximal and optimized drug treatment, including 
low-dose spironolactone whenever possible.19
As in the Dutch study,18 patients found to be ineligible for 
RDN in our current study were older and had lower office and 
ambulatory blood pressures and medication scores. Although 
the proportion of patients eligible for RDN was of the same 
Table 1. Main Characteristics of Patients Referred for RDN According to Eligibility Status
Characteristics All Patients n=731
E2 Patients  
n=290 (39.7%)
Non-E2 Patients  
n=441 (60.3%)
Women, n (%) 336 (46.0) 122 (42.1) 214 (48.5)
Age, y 61.6±12.0 60.0±11.3 62.7±14.4*
White, n (%) 701 (95.9) 276 (95.2) 425 (96.4)
Office systolic pressure, mm Hg 176.7±27.2 183.8±27.6 172.1±25.9†
Office diastolic pressure, mm Hg 96.2±16.8 100.9±17.1 93.2±16.0†
24-h systolic pressure, mm Hg 154.7±20.1 160.7±17.9 149.8±20.5†
24-h diastolic pressure, mm Hg 89.5±14.6 94.4±13.6 85.5±14.2†
No. of drug classes 4.1±1.6 4.3±1.8 3.9±1.5*
Body mass index, kg/m2 30.0±5.6 29.0±5.8 30.2±5.5
Diabetes mellitus, n (%) 184/668 (27.5) 75/278 (27.0) 109/390 (28.0)
Coronary artery disease, n (%) 134/667 (20.1) 54/277 (19.5) 80/390 (20.5)
Stroke, n (%) 44/457 (9.6) 14/171 (8.2) 30/286 (10.5)
Peripheral artery disease, n (%) 83/665 (12.5) 33/278 (11.9) 50/387 (12.9)
eGFR classes, mL/min per 1.73 m2 73.8±22.5 76.1±21.7 72.3±22.9‡
n=686 n=275 n=411
<30 15 (2.2) 2 (0.7) 13 (3.2)
30–45 64 (9.3) 19 (6.9) 45 (11.0)
≥45 607 (88.5) 254 (92.4) 353 (85.9)
Data are mean±SD or number of patients (%). E2 indicates patients eligible for renal denervation according to the centers’ own 
criteria; eGFR, estimated glomerular filtration rate; non-E2, patients ineligible for renal denervation according to the centers’ own 
criteria; and RDN, renal denervation.
Difference between E2 and non-E2 patients: *P<0.01, †P<0.001, ‡P<0.05. Difference in the eGFR classification between E2 
and non-E2: P=0.017.
 at K.U. Leuven (KUL) on May 8, 2014http://hyper.ahajournals.org/Downloaded from 
1322  Hypertension  June 2014
order of magnitude in the Dutch and our study (33.1% versus 
39.7%), the leading causes of ineligibility substantially dif-
fered. In particular, whereas in the Dutch cohort,18 success-
ful treatment adjustment excluded only 12% of the referred 
patients from RDN, in our European cohort, treatment optimi-
zation allowed to control blood pressure in ≈50% of noneli-
gible patients, despite the fact that most patients were referred 
because blood pressure control was considered impossible to 
achieve, often after years of unsuccessful attempts.
In half of cases (Figure 1), treatment adjustment involved 
prescription of low-dose spironolactone (25–50 mg/d). 
Additional changes might have included prescription of other 
drug classes, optimization of the dose of diuretics and stepped 
care combination of diuretics acting at different nephron seg-
ments (sequential nephron blockade),21 use of more potent 
or long-acting drugs, and use of double or triple fixed drug 
combinations to increase drug adherence. One might also 
hypothesize that consultation in a specialized center and the 
perspective of use of RDN, an invasive and still exceptional 
procedure, might have convinced a proportion of patients 
to adhere more strictly to their drug treatment, which may 
explain substantial blood pressure improvements observed in 
some patients despite minimal treatment changes.
Once more, the proportion of patients amenable to blood 
pressure control might be an underestimation because not 
all investigators attempted to obtain maximal treatment in 
all patients. One may expect that the proportion is higher in 
unselected cohorts of patients with resistant hypertension. 
These findings are at odds with the frequent belief, held by 
some investigators and disseminated by the device industry 
that, for patients with resistant hypertension, per definition, 
no reasonable further pharmaceutical options are available.22 
They highlight the importance of skilful treatment adjustment 
and the important role of hypertension tertiary referral centers 
as gatekeepers before RDN is considered.
The effect of treatment optimization should also be inter-
preted in the light of the drug regimen at the first referral visit, 
which was neither maximal nor optimal in a substantial pro-
portion of patients. In line with the data published by Hanselin 
et al,23 the association of 2 or even 3 renin–angiotensin sys-
tem blockers, a less efficacious and potentially harmful drug 
combination,24,25 was used in 22% of patients, whereas diuret-
ics (82%) and, notably, calcium antagonists (73%) were still 
underused. In particular, low-dose spironolactone, a recom-
mended drug in patients with resistant hypertension26,27 was 
prescribed in only 26% of patients (Table 2), even in a sub-
set with normal renal function, which is much higher than 
in the US database explored by Hanselin et al23 (5.9%) and 
slightly better than in 2 other cohorts of patients referred in 





Eligible According to SYMPLICITY 
HTN-2 Criteria (E1) Number (%), 95% 
Confidence Interval
Eligible According to Centers’ Own 
Criteria (E2) Number (%), 95% 
Confidence Interval
Lausanne 53 19 (35.9), 23.0–48.8 14 (26.4), 14.5–38.3
Geneva 32 16 (50.0), 32.7–67.3 12 (37.5), 20.7–54.3
Hannover 91 44 (48.4), 38.1–58.7 48 (52.8), 42.5–63.1
Prague 18 14 (77.8), 58.6–97.0 4 (22.2), 3.0–41.4
Oslo 18 10 (55.6), 32.6–78.6 6 (33.3), 11.5–55.1
Stockholm 21 15 (71.4), 52.1–90.7 17 (81.0), 64.2–97.8
Odense 64 7 (10.9), 3.3–18.5 7 (10.9), 3.3–18.5
Glasgow 52 33 (64.5), 51.5–77.5 25 (48.1), 34.5–61.7
Brussels 91 31 (34.1), 24.2–43.8 33 (36.3), 26.4–46.2
Utrecht 274 … 119 (43.4), 37.5–49.3
Krakow 17 5 (29.4), 7.7–51.1 5 (29.4), 7.7–51.1
All centers 731 194/457 (42.5), 38.0–47.1 290/731 (39.7), 36.2–43.2
RDN indicates renal denervation.
Table 2. Drug Treatment of Patients Referred for Renal 
Denervation at the First Visit Before Treatment Adjustment
Drug Treatment No. of Patients
Total number 692
Antihypertensive drug classes, n 4.1±1.6
Inhibitors of the renin–angiotensin system
  Total 589 (85.1)
  Converting enzyme inhibitors (n=418) 180 (43.1)
  Angiotensin receptor blockers (n=418) 223 (53.4)
  Aliskiren (n=418) 60 (14.4)
  ≥2 inhibitors of the renin system (n=418) 90 (21.5)
Calcium channel blockers 504 (72.8)
Diuretics
  Total 568 (82.0)
  Thiazide (n=418) 279 (66.8)
  Loop diuretic (n=418) 120 (28.7)
  Spironolactone 180 (26.0)
β-Blockers 498 (71.9)
α-Blockers 141 (20.4)
Centrally acting drugs 175 (25.3)
Vasodilators 42 (6.1)
The Utrecht center did not have detailed information on file on the 
subclassification of renin system inhibitors or diuretics.
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hypertension expert centers (24%)18,19 but clearly remains 
below expectations. Indeed, although spironolactone was tried 
in the past but stopped at the time of referral in the expert 
center in ≈20% additional patients, likely because of poor effi-
cacy or drug intolerance, half of patients were never exposed 
to a mineralocorticoid receptor antagonist.
The frequency of other causes of ineligibility for RDN 
deserves specific comments. Compared with Simplicity 
 HTN-2,4 the proportion of patients excluded for anatomic rea-
sons was similar (17% versus 24%), despite the fact that, in 
our cohort, patients with multiple renal arteries were consid-
ered as eligible, provided the length and diameter of the main 
renal arteries were ≥20 mm and 4 mm, respectively.4 Although 
the low frequency of white-coat–resistant hypertension (8% 
versus 38% in the Spanish registry on ambulatory blood pres-
sure monitoring)28 likely reflects preselection by referring 
physicians, the prevalence of secondary hypertension was 
similar to that reported in other studies (12%),18,29 despite the 
fact that most patients were referred by specialists.
This study has to be interpreted within the context of its lim-
itations, the most important being the heterogeneity in refer-
ral and eligibility criteria, screening, selection, and treatment 
algorithms between the different centers. Second, the exact 
nature and dosage of drugs used, proportion of  single-pill 
versus fixed-dose combinations, and the precise strategy 
used by each center for treatment adjustment were not avail-
able. Finally, drug adherence was not evaluated according to 
standardized methods in all centers. However, our study, the 
largest conducted thus far, has the advantage of involving mul-
tiple centers, thus providing a more representative overview of 
screening for RDN in European hypertension centers. It also 
generated information on the effect of treatment adjustment 
in resistant hypertension. Furthermore, the limitations men-
tioned previously might only have led to an underestimation 
of the proportion of ineligible patients, and in particular of 
patients amenable to blood pressure target after drug treatment 
optimization, and thus are unlikely to affect the key messages 
of this study. These are (1) only a minority of patients referred 
for RDN are eligible for the technique; (2) the most frequent 
cause of ineligibility (46.9%) was blood pressure normaliza-
tion after treatment adjustment in the expert center; and (3) 
in more than half of patients successfully controlled by drug 
treatment optimization, low-dose spironolactone was part of 
the therapeutic arsenal.
Perspectives
In view of the persistent uncertainties on the safety and effi-
cacy of RDN—further emphasized by the recent announce-
ment of the failure of SYMPLICITY HTN-330 to reach its 
primary efficacy end point (http://www.tctmd.com/show.
aspx?id=123265)—difficult to treat patients and patients with 
resistant hypertension should be thoroughly evaluated in an 
expert hypertension center before RDN is considered (http://
www.bcs.com/pages/news_full.asp?NewsID=19792021). 
More generally, the availability of RDN as last-line treatment 
for patients with resistant hypertension is a unique opportu-
nity to revisit the diagnostic and therapeutic algorithms of 
resistant hypertension and to increase awareness about the 
best diagnostic and therapeutic strategies in this small sub-
set of patients with hypertension. Finally, although current 
eligibility criteria are mostly based on SYMPLICITY HTN-
24 and medical common sense, future works should focus on 
the identification of patients most likely to benefit from RDN, 
with the lowest probability of adverse events or complications. 
In particular, identification of predictive factors of blood pres-
sure response post-RDN is a priority. In this respect, our first 
study on the efficacy of RDN within the ENCOReD network 
suggested a higher probability of blood pressure response in 
patients with established cardiovascular disease.8 Conversely, 
higher baseline serum creatinine was associated with lower 
probability of blood pressure improvement after RDN.8 
Figure 1. Reasons of noneligibility for renal denervation after 
thorough work-up and treatment optimization in 11 expert 
hypertension centers. For each patient, several reasons of 
noneligibility could be applicable (see Figure 2). Only reasons 
with a frequency of ≥5% were plotted.
Figure 2. Main reasons of noneligibility of patients with resistant 
hypertension screened for renal denervation. BP indicates blood 
pressure; and HT, hypertension.
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Although preliminary, these results may pave the way toward 
identification of responder and nonresponder profiles in cur-
rently planned or ongoing randomized controlled studies.
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What Is New?
•	 In a multicenter European cohort of 731 patients referred for renal dener-
vation to leading hypertension centers, only ≈40% qualified.
•	The most frequent cause of ineligibility (46.9%) was blood pressure nor-
malization after treatment adjustment in the expert center, removing the 
indication for renal denervation.
•	Other reasons of ineligibility included incompatible renal artery anatomy 
(17.0%) and secondary hypertension (11.1%).
What Is Relevant?
•	The diagnosis of resistant hypertension requires out-of-the-office blood 
pressure monitoring.
•	Management of resistant hypertension by combining antihypertensive 
drugs in optimal doses and combinations is substandard in Europe, high-
lighting the need for continuing education of physicians.
•	Renal denervation remains a last-resort approach that should only be 
applied at expert hypertension centers in a context of clinical research. 
The failure of SYMPLICITY HTN-3 to reach its primary end point of ef-
ficacy supports this contention.
•	Hypertension expert centers should be the gatekeepers to give patients 
access to renal denervation.
Summary
This study showed that in 731 patients representative for clinical 
practice at 11 European hypertension expert centers (mean age, 
61.6 years; office blood pressure, 177/96 mm Hg, number of drugs, 
4.1), only 39.7% of patients referred for renal denervation quali-
fied. The main reasons of noneligibility were normalization of blood 
pressure after treatment adjustment (46.9%), incompatible renal 
artery anatomy (17.0%), and previously undetected secondary hy-
pertension (11.1%).
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Table S1 Reasons of non-eligibility for renal denervation after thorough work-up and treatment adaptation in the centers 
(E2) (starts)  
Center name  Non-E2  patients  
Blood pressure  controlled after 
treatment adjustment  
 Anatomical reasons  
Spirolac-
tone  









Other  Total  
Lausanne 39 8 (20.5) 8 (20.5) 16 (41.0)  2 (5.1) 1 (2.6)  4 (10.3)  5 (12.8)  
Geneva 20 4 (20.0) 4 (20.0) 8 (40.0)  0 0 0 0 
Hannover 43 22 (51.2) 17 (39.5) 39 (90.7)  1 (2.3) 0 0 1 (2.3) 
Prague 14 1 (7.1) 7 (50.0) 8 (57.1)  0 0 0 0 
Oslo 12 0 1 (8.3) 1 (8.3)  0 0 1 (8.3) 1 (8.3) 
Stockholm 4 0 2 (50.0) 2 (50.0)  0 1 (25.0) 0 1 (25.0) 
Odense 57 17 (29.8) 22 (38.6) 39 (68.4)  4 (7.0) 0 3 (5.3) 7 (12.3) 
Glasgow 27 3 (11.1) 2 (7.4) 5 (18.5)  2 (7.7) 0 10 (37.0) 12 (44.4) 
Brussels 58 20 (34.5) 12 (20.7) 32 (55.2)  4 (6.9) 5 (8.6) 10 (17.2) 17 (29.3) 
Utrecht 155 NA NA 54 (34.8)  14 (9.0) 4 (2.6) 5 (3.2) 23 (14.8) 
Krakow 12 1 (8.3) 2 (16.7) 3 (25.0)  3 (25.0) 0 5 (41.7) 8 (66.7) 
11 centers 441 76 77 207 (46.9)  30 (6.8) 11 (2.5) 38 (8.6) 75 (17.0) 
NA indicates information not available. Data are number of patients (%). The table includes reasons for non-eligibility with a 
frequency of at least 5%.  Numbers do not add up, because patients could have more than one reason making them ineli-
gible.  
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Other cause Total 
Lausanne 7 (18.0) 1 (2.6) 8 (20.5) 9 (23.1) 12 (30.8) 1 (2.6) 3 (12.5) 
Geneva 0 0 0 2 (10.0) 1 (5.0) 6 (30.0) 3 (15.0) 
Hannover 0 0 0 0 2 (4.7) 0 3 (7.0) 
Prague 4 (28.6) 0 4 (28.6) 0 0 7 (50.0) 3 (21.4) 
Oslo 0 0 0 0 0 5 (41.7) 0 
Stockholm 0 1 (25.0) 1 (25.0) 1 (25.0) 0 0 1 (25.0) 
Odense 1 (1.8) 0 1 (1.8) 13 (22.8) 9 (15.9) 6 (10.5) 4 (7.0) 
Glasgow 0 3 (11.1) 3 (11.1) 2 (7.4) 3 (11.1) 2 (7.4) 2 (7.4) 
Brussels 0 0 0 12 (20.7) 8 (13.8) 6 (10.3) 0 
Utrecht 25 (16.1) 4 (2.6) 29 (18.7) NA NA NA 9 (6%) 
Krakow 0 3 (25.0) 3 (25.0) 1 (8.3) 0 1 (8.3) 6 (50%) 
11 centers 37 (8.4) 12 (2.7) 49 (11.1) 40 (9.1) 35 (7.9) 34 (7.7) 34 (7.7) 
Data are number of patients (%). Reasons of non-eligibility declared in < 5% of cases are not indicated. NA: not available.   




Figure S1   Proportion of prescribed antihypertensive drug classes in patients re-
ferred for renal denervation, before treatment adjustment in the 11 expert centers.   
RAS inhibitors refer to renin angiotensin inhibitors (includes angiotensin converting 
enzyme inhibitors, angiotensin II receptor antagonists and the direct renin inhibitor 
aliskiren).   CCBs refers to calcium channel blockers.    
 
